A Phase 2 interventional study of Pemetrexed in Nonsquamous Non-Small Cell Neoplasm of Lung, Non-Small Cell Lung Cancer Metastatic and Non-Small Cell Lung Cancer Stage IIIB, sponsored by Eli Lilly and Company. Completed at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-06.
Sponsored by Eli Lilly and Company · Phase 2 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 21 open to participants now, 32 under way, 11 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.
Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 118th largest by enrollment of the 223 interventional ones that give a count, is one of 5 that started in 2011, is one of 128 in phase 2, and was the 115th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →21 of the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Belgium, Brazil and 17 more countries
Ages 18+
Guangzhou Medical University · Sites in China
Ages 18–75
Second Affiliated Hospital of Nanchang University · Sites in China
Ages 18–85
Shanghai Chest Hospital · Sites in China
Ages 18+
Taipei Veterans General Hospital, Taiwan · Sites in Taiwan
Ages 20+
By country, each count listing its studies:
Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
227 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 148 · Phase 3 47 · Phase 4 8
First in 2001; this study’s year is marked. 5 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 52 is below the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 64 across the 223 interventional studies. Of the 161 that completed or were terminated, 89 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 227 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company: 6 open now, 20 under way, 6 of them phase 3. Of 121 finished, 81 (67%) have results posted.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 102nd largest by enrollment of the 139 interventional ones that give a count, is one of 4 that started in 2011, is one of 73 in phase 2, and was the 90th registered.
Eli Lilly and Company’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
7 of the studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04585490Phase 3Stanford UniversityAdaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC | 2026-12 |
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT03178552Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | 2027-06-30 |
| NCT05805631Taipei Veterans General Hospital, TaiwanIntrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC | 2026-12-31 |
| NCT06440954Hunan Province Tumor HospitalEfficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Eli Lilly and Company’s 147 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The main purpose for this study is to answer the following research questions:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Meet the following guidelines if the participant has received prior radiation therapy:
Have adequate organ function, including:
Are willing to comply with the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
500 milligrams per square meter (mg/m\^2) pemetrexed administered intravenously over approximately 10 minutes on Day 1 of a 21-day cycle. Maintenance therapy administered until disease progression or the participant is discontinued for any other reason. The first dose of maintenance therapy will be administered at the hospital; thereafter, therapy will be administered in the home setting by qualified oncology homecare nurses.
Drug: Pemetrexed
Administered intravenously
Also known as: LY231514, Alimta, Pemetrexed disodium, Pemetrexed sodium hydrate
Percentage of Participants Who Adhered to Treatment Administration at Home
Participants were considered adherent from the time of the first dose in Cycle 1 (hospital administration) until either the last day of the cycle when the participant reverted to pemetrexed hospital administration or the last day of the cycle when the participant discontinued study treatment or the study for reasons related to the home setting. The percentage of participants who adhered to treatment administration at home was estimated by a Kaplan-Meier survival analyses approach. Participants who died or discontinued the study and treatment without reverting to hospital administration were censored at the time of discontinuation.
Time frame: Cycle 1, Day 1 through Cycle 19, Day 1 and Cycle 19, Day 1 (21 days/cycle)
Change From Baseline in the European Quality of Life Instrument (EQ-5D) Visual Analogue Scale (VAS)
The EQ-5D scale was used to provide an estimate of the health state utility in this population. The EQ-5D scale includes a 5-dimensional descriptive system that measures each of the health state attributes: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression according to a 3-point scale (no problem, some problems, and major problems) and a VAS that allows participants to rate their present health condition from 0 (worst imaginable health state) to 100 (best imaginable health state). The change from baseline in EQ-5D VAS is reported.
Time frame: Baseline, Day 1 of Cycles 2 and 4 (21 days/cycle) and 30 days post treatment discontinuation
Change From Baseline in the EQ-5D Index Score
The EQ-5D scale was used to provide an estimate of the health state utility in this population. The EQ-5D scale includes a 5-dimensional descriptive system that measures each of the health state attributes: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression according to a 3-point scale (no problem, some problems, and major problems) and a VAS that allows participants to rate their present health condition from 0 (worst imaginable health state) to 100 (best imaginable health state). The change from baseline EQ-5D Index score is reported and the EQ-5D Index score was calculated by converting health state scores into a weighted health state index according to a United Kingdom population-based algorithm. The possible values for the EQ-5D Index score range from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension), on a scale where 1 represents the best possible health state.
Time frame: Baseline, Day 1 of Cycles 2 and 4 (21 days/cycle) and 30 days post treatment discontinuation
Maximum Improvement Over Baseline in Individual Lung Cancer Symptoms Scale (LCSS) Item Scores
LCSS is a 9-item questionnaire; 6 items are symptom-specific measures for lung cancer (loss of appetite, fatigue, cough, dyspnea, hemoptysis, and pain), and 3 summation items describe overall symptomatic distress, interference with activity level, and overall quality of life during the past 24 hours. Participant responses were measured using a VAS with 100-millimeter (mm) lines. Scores ranged from 0 mm (no symptoms and no impact on activities, quality of life) to 100 mm (symptoms as bad as they could be, impacting activities and quality of life).
Time frame: Baseline, Day 1 of each cycle (up to Cycle 19, 21 days/cycle), and 30 days post treatment discontinuation
Participant Satisfaction: Chemotherapy at Hospital
Participants were asked to evaluate their hospital experiences in this study by answering 4 questions (Q). Q1: "What do you consider advantages of having chemotherapy at the hospital? Choose all that apply." Choices included: "Support from other patients", "Access to other medical specialists", "Access to more technical services", "Safer in case something goes wrong", and "Other". Q2: "What do you consider disadvantages of having chemotherapy at the hospital? Choose all that apply." Choices included: "Need to travel", "Having to wait for treatment", "Not having a personalized treatment", "Lack of privacy on the ward", and "Other". Q3: "How would you rate your overall satisfaction with chemotherapy at the hospital?" and Q4: "How would you rate your overall satisfaction with the nursing staff during chemotherapy at the hospital?" Choices for Q3 and Q4 included: "Very dissatisfied", "Somewhat dissatisfied", "Neither satisfied nor dissatisfied", "Somewhat satisfied", or "Very satisfied".
Time frame: The first evaluation completed at either Cycle 4, Day 1 (21 days/cycle) or 30 days post treatment discontinuation
Participant Satisfaction: Chemotherapy at Home
Participants were asked to evaluate their home treatment experiences in this study by answering 4 questions (Q). Q5: "What do you do consider advantages of having chemotherapy at home? Choose all that apply." Choices included: "No need to travel", "Not having to wait for treatment", "Personalized service", "More privacy", and "Other". Q6:"What do you consider disadvantages of having chemotherapy at home? Choose all that apply." Choices included: "Lack of other patients' support", "Extra burden for family/friends", "Safety concerns", "Need to rely on 1 medical specialist", and "Other". Q7: "How would you rate your overall satisfaction with chemotherapy at home?" Choices included: "Very dissatisfied", "Somewhat dissatisfied", "Neither satisfied nor dissatisfied", "Somewhat satisfied", or "Very satisfied".
Time frame: The first evaluation completed at either Cycle 4, Day 1 (21 days/cycle) or 30 days post treatment discontinuation
Participant Satisfaction: Regarding the Study Nurse
Participants were asked 7 questions (Q) about their study nurse for home treatment. Q8: "Was the nurse an easy person to talk to?", Q9: "When the nurse came, did you feel he/she had enough time to do the required things?", Q10: "Do you think the nurse had time to discuss things with you?", Q11: "Did you feel that the nurse knew enough about you and your illness?" Choices for Q8 through Q11 included: "Yes" or "No". Q12: "Were you able to get all the information you wanted about your illness or treatment?" Choices included: "Yes", "No", or "Uncertain". Q13: "Would you say that the nurse gave..." Choices included: "a lot of reassurance and support", "some reassurance and support", or "hardly any reassurance and support". Q14: "How would you rate your overall satisfaction with the nursing staff during chemotherapy at home?" Choices included: "Very dissatisfied", "Somewhat dissatisfied", "Neither satisfied nor dissatisfied", "Somewhat satisfied", or "Very satisfied".
Time frame: The first evaluation completed at either Cycle 4, Day 1 (21 days/cycle) or 30 days post treatment discontinuation
Participant Satisfaction: Preferences Regarding Home and/or Hospital Treatment
Participants were asked to evaluate their preferences regarding home and/or hospital treatment delivery in this study by answering 2 questions (Q). Q15: "Do you prefer having your chemotherapy at home or at the hospital, or are you indifferent?" Choices included: "Home", "Hospital", or "Indifferent". Q16: "Would you recommend having chemotherapy at home to someone else in your same situation?" Choices included: "Yes", "No", or "Not sure".
Time frame: The first evaluation completed at either Cycle 4, Day 1 (21 days/cycle) or 30 days post treatment discontinuation
Physician Satisfaction: Distant Management of Participant
The physician was asked, "How would you rate your overall satisfaction with the distant management of the participant during chemotherapy at home?" Choices included: "Very dissatisfied", "Somewhat dissatisfied", "Neither satisfied nor dissatisfied", "Somewhat satisfied", or "Very satisfied".
Time frame: 30 days post treatment discontinuation
Resource Utilization: Number of Participants With an Unplanned Use of Healthcare Resources
The number of participants who had at least 1 unplanned use of health care resources \[accident and emergency department (dept.), specialists \[oncologist, pulmonologist, etcetera (etc.)\], general practitioner (GP) or family doctor, or diagnostic procedures\] during the study is reported.
Time frame: Cycle 1, Day 1 through last day of cycle when participant reverted to hospital administration or discontinued (up to Cycle 19, 21 days/cycle)
Resource Utilization: Unplanned Health Care Visits, Consultations, and Diagnostic Services
The unplanned use of any 1 of the following 4 resources is reported, as well as the unplanned use of each resource: accident and emergency dept., specialists (oncologist, pulmonologist etc.), GP or family doctor, and diagnostic procedures. Results are reported as the number of participants with an unplanned resource use (visit) for a specified number of times.
Time frame: Cycle 1, Day 1 through last day of cycle when participant reverted to hospital administration or discontinued (up to Cycle 19, 21 days/cycle)
Resource Utilization: Duration of Health Care Visits
The duration of the health care visit in the home setting is reported. The visit started when the nurse arrived and included the entire treatment process. The visit ended when the nurse left the home setting. Due to the limited number of participants with evaluable data, results are reported for Cycles 2 through 4.
Time frame: Cycle 2, Day 1 through last day of cycle when participant reverted to hospital administration or discontinued (up to Cycle 4, 21 days/cycle)
Resource Utilization: Distances Traveled
The distance traveled is reported by region (Great Britain and Sweden) and includes the distance traveled by the participant from his/her home to the hospital (Cycle 1) and other cycles where the homecare nurse traveled from the hospital to the participant's home. Due to the limited number of participants with evaluable data, results are reported for Cycles 1 through 4.
Time frame: Cycle 1, Day 1 through last day of cycle when participant reverted to hospital administration or discontinued (up to Cycle 4, 21 days/cycle)
Overall Survival (OS) at 6 Months
The percentage of participants who were alive at Month 6 was calculated as a cumulative percentage by Kaplan-Meier survival analyses approach. For participants not known to have died as of the cut-off date, OS was censored as the last contact date (known alive).
Time frame: Cycle 1, Day 1 to the date of death from any cause (up to Month 6)
Time to Treatment Failure (TTF)
The time from the date of the first dose of study treatment (Cycle 1, Day 1) to the date of death from any cause, PD (clinical and objective), or discontinuation of pemetrexed due to toxicity. Response was defined using RECIST, v1.1 criteria. PD was defined as having at least a 20% increase in the sum of the longest diameter of target lesions and at a minimum 5 mm increase above nadir. TTF was censored at the date of the last visit for participants who did not discontinue pemetrexed, who were still alive, and who had not progressed.
Time frame: Cycle 1, Day 1 to first event (up to Cycle 19, 21 days/cycle)
Number of Participants Who Had Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), or Died
The number of participants who had at least 1 TEAE or serious TEAE (regardless of causality) is reported along with the number of participants who died (due to any cause) while on therapy or during treatment discontinuation follow-up (up to 6 months). TEAEs started on or after the date and time of first dose of study drug, or started prior to study drug but worsened after study drug started. Clinically significant events were defined as SAEs and other non-serious adverse events (AEs). A summary of SAEs and other non-serious AEs is located in the Reported Adverse Events module.
Time frame: First dose of study drug (Cycle 1, Day 1) through study completion [up to Cycle 19 (21 days/cycle) or treatment discontinuation, plus up to 6 months post treatment discontinuation]
| Milestone | Pemetrexed |
|---|---|
| Started | 52 |
| Received at least 1 dose of study drug | 52 |
| Completed | 51 |
| Not completed | 1 |
| Withdrew: Lost to fu post tx discontinuation | 1 |
Participants were considered adherent from the time of the first dose in Cycle 1 (hospital administration) until either the last day of the cycle when the participant reverted to pemetrexed hospital administration or the last day of the cycle when the participant discontinued study treatment or the study for reasons related to the home setting. The percentage of participants who adhered to treatment administration at home was estimated by a Kaplan-Meier survival analyses approach. Participants who died or discontinued the study and treatment without reverting to hospital administration were censored at the time of discontinuation.
| percentage of participants | Pemetrexed |
|---|---|
| Cycle 1, Hospital Delivery | 100 (100 to 100) |
| Cycle 2, Home Delivery | 98.0 (86.4 to 99.7) |
| Cycle 3, Home Delivery | 98.0 (86.4 to 99.7) |
| Cycle 4, Home Delivery | 98.0 (86.4 to 99.7) |
| Cycle 5, Home Delivery | 98.0 (86.4 to 99.7) |
| Cycle 6, Home Delivery | 98.0 (86.4 to 99.7) |
| Cycle 7, Home Delivery | 90.7 (61.7 to 98.1) |
| Cycle 8, Home Delivery | 90.7 (61.7 to 98.1) |
| Cycle 9, Home Delivery | 90.7 (61.7 to 98.1) |
| Cycle 10, Home Delivery | 90.7 (61.7 to 98.1) |
| Cycle 11, Home Delivery | 90.7 (61.7 to 98.1) |
| Cycle 12, Home Delivery | 90.7 (61.7 to 98.1) |
| Cycle 13, Home Delivery | 90.7 (61.7 to 98.1) |
| Cycle 14, Home Delivery | 90.7 (61.7 to 98.1) |
| Cycle 15, Home Delivery | 90.7 (61.7 to 98.1) |
| Cycle 16, Home Delivery | 90.7 (61.7 to 98.1) |
| Cycle 17, Home Delivery | 90.7 (61.7 to 98.1) |
| Cycle 18, Home Delivery | 90.7 (61.7 to 98.1) |
| Cycle 19, Home Delivery | 90.7 (61.7 to 98.1) |
The EQ-5D scale was used to provide an estimate of the health state utility in this population. The EQ-5D scale includes a 5-dimensional descriptive system that measures each of the health state attributes: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression according to a 3-point scale (no problem, some problems, and major problems) and a VAS that allows participants to rate their present health condition from 0 (worst imaginable health state) to 100 (best imaginable health state). The change from baseline in EQ-5D VAS is reported.
| units on a scale | Pemetrexed |
|---|---|
| Cycle 2 (n=34) | 3.0 ± 18.6 |
| Cycle 4 (n=20) | 7.7 ± 21.7 |
| 30 days post treatment discontinuation (n=22) | -0.9 ± 18.9 |
The EQ-5D scale was used to provide an estimate of the health state utility in this population. The EQ-5D scale includes a 5-dimensional descriptive system that measures each of the health state attributes: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression according to a 3-point scale (no problem, some problems, and major problems) and a VAS that allows participants to rate their present health condition from 0 (worst imaginable health state) to 100 (best imaginable health state). The change from baseline EQ-5D Index score is reported and the EQ-5D Index score was calculated by converting health state scores into a weighted health state index according to a United Kingdom population-based algorithm. The possible values for the EQ-5D Index score range from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension), on a scale where 1 represents the best possible health state.
| units on a scale | Pemetrexed |
|---|---|
| Cycle 2 (n=38) | 0.03 ± 0.22 |
| Cycle 4 (n=23) | 0.08 ± 0.22 |
| 30 days post treatment discontinuation (n=26) | -0.9 ± 0.28 |
LCSS is a 9-item questionnaire; 6 items are symptom-specific measures for lung cancer (loss of appetite, fatigue, cough, dyspnea, hemoptysis, and pain), and 3 summation items describe overall symptomatic distress, interference with activity level, and overall quality of life during the past 24 hours. Participant responses were measured using a VAS with 100-millimeter (mm) lines. Scores ranged from 0 mm (no symptoms and no impact on activities, quality of life) to 100 mm (symptoms as bad as they could be, impacting activities and quality of life).
| mm | Pemetrexed |
|---|---|
| Loss of Appetite (n=43) | 16.3 ± 22.0 |
| Fatigue (n=43) | 24.5 ± 27.2 |
| Cough (n=41) | 9.2 ± 19.7 |
| Dyspnea (n=41) | 17.2 ± 26.7 |
| Hemoptysis (n=43) | 0.4 ± 4.3 |
| Pain (n=40) | 11.8 ± 25.1 |
| Overall Symptomatic Distress (n=43) | 8.3 ± 22.3 |
| Interference With Activity Level (n=43) | 15.3 ± 25.1 |
| Overall Quality of Life (n=41) | 12.2 ± 23.0 |
Participants were asked to evaluate their hospital experiences in this study by answering 4 questions (Q). Q1: "What do you consider advantages of having chemotherapy at the hospital? Choose all that apply." Choices included: "Support from other patients", "Access to other medical specialists", "Access to more technical services", "Safer in case something goes wrong", and "Other". Q2: "What do you consider disadvantages of having chemotherapy at the hospital? Choose all that apply." Choices included: "Need to travel", "Having to wait for treatment", "Not having a personalized treatment", "Lack of privacy on the ward", and "Other". Q3: "How would you rate your overall satisfaction with chemotherapy at the hospital?" and Q4: "How would you rate your overall satisfaction with the nursing staff during chemotherapy at the hospital?" Choices for Q3 and Q4 included: "Very dissatisfied", "Somewhat dissatisfied", "Neither satisfied nor dissatisfied", "Somewhat satisfied", or "Very satisfied".
| participants | Pemetrexed |
|---|---|
| Q1, Support from other patients | 8 |
| Q1, Access to other medical specialists | 19 |
| Q1, Access to more technical services | 12 |
| Q1, Safer in case something goes wrong | 19 |
| Q1, Other | 3 |
| Q2, Need to travel | 36 |
| Q2, Having to wait for treatment | 27 |
| Q2, Not having a personalized treatment | 5 |
| Q2, Lack of privacy on the ward | 7 |
| Q2, Other | 1 |
| Q3, Very dissatisfied | 0 |
| Q3, Somewhat dissatisfied | 3 |
| Q3, Neither satisfied nor dissatisfied | 3 |
| Q3, Somewhat satisfied | 11 |
| Q3, Very satisfied | 21 |
| Q4, Very dissatisfied | 3 |
| Q4, Somewhat dissatisfied | 0 |
| Q4, Neither satisfied nor dissatisfied | 0 |
| Q4, Somewhat satisfied | 3 |
| Q4, Very satisfied | 32 |
Participants were asked to evaluate their home treatment experiences in this study by answering 4 questions (Q). Q5: "What do you do consider advantages of having chemotherapy at home? Choose all that apply." Choices included: "No need to travel", "Not having to wait for treatment", "Personalized service", "More privacy", and "Other". Q6:"What do you consider disadvantages of having chemotherapy at home? Choose all that apply." Choices included: "Lack of other patients' support", "Extra burden for family/friends", "Safety concerns", "Need to rely on 1 medical specialist", and "Other". Q7: "How would you rate your overall satisfaction with chemotherapy at home?" Choices included: "Very dissatisfied", "Somewhat dissatisfied", "Neither satisfied nor dissatisfied", "Somewhat satisfied", or "Very satisfied".
| participants | Pemetrexed |
|---|---|
| Q5, No need to travel | 37 |
| Q5, Not having to wait for treatment | 27 |
| Q5, Personalized service | 28 |
| Q5, More privacy | 20 |
| Q5, Other | 2 |
| Q6, Lack of other patients' support | 5 |
| Q6, Extra burden for family/friends | 1 |
| Q6, Safety concerns | 4 |
| Q6, Need to rely on 1 medical specialist | 7 |
| Q6, Other | 19 |
| Q7, Very dissatisfied | 1 |
| Q7, Somewhat dissatisfied | 0 |
| Q7, Neither satisfied nor dissatisfied | 2 |
| Q7, Somewhat satisfied | 1 |
| Q7, Very Satisfied | 30 |
Participants were asked 7 questions (Q) about their study nurse for home treatment. Q8: "Was the nurse an easy person to talk to?", Q9: "When the nurse came, did you feel he/she had enough time to do the required things?", Q10: "Do you think the nurse had time to discuss things with you?", Q11: "Did you feel that the nurse knew enough about you and your illness?" Choices for Q8 through Q11 included: "Yes" or "No". Q12: "Were you able to get all the information you wanted about your illness or treatment?" Choices included: "Yes", "No", or "Uncertain". Q13: "Would you say that the nurse gave..." Choices included: "a lot of reassurance and support", "some reassurance and support", or "hardly any reassurance and support". Q14: "How would you rate your overall satisfaction with the nursing staff during chemotherapy at home?" Choices included: "Very dissatisfied", "Somewhat dissatisfied", "Neither satisfied nor dissatisfied", "Somewhat satisfied", or "Very satisfied".
| participants | Pemetrexed |
|---|---|
| Q8, Yes | 37 |
| Q8, No | 0 |
| Q9, Yes | 36 |
| Q9, No | 1 |
| Q10, Yes | 37 |
| Q10, No | 1 |
| Q11, Yes | 36 |
| Q11, No | 0 |
| Q12, Yes | 34 |
| Q12, No | 0 |
| Q12, Uncertain | 3 |
| Q13, Hardly any reassurance and support | 0 |
| Q13, Some reassurance and support | 2 |
| Q13, A lot of reassurance and support | 35 |
| Q14, Very dissatisfied | 3 |
| Q14, Somewhat dissatisfied | 0 |
| Q14, Neither satisfied nor dissatisfied | 1 |
| Q14, Somewhat satisfied | 1 |
| Q14, Very satisfied | 33 |
Participants were asked to evaluate their preferences regarding home and/or hospital treatment delivery in this study by answering 2 questions (Q). Q15: "Do you prefer having your chemotherapy at home or at the hospital, or are you indifferent?" Choices included: "Home", "Hospital", or "Indifferent". Q16: "Would you recommend having chemotherapy at home to someone else in your same situation?" Choices included: "Yes", "No", or "Not sure".
| participants | Pemetrexed |
|---|---|
| Q15, Home | 33 |
| Q15, Hospital | 0 |
| Q15, Indifferent | 5 |
| Q16, Yes | 37 |
| Q16, No | 0 |
| Q16, Not sure | 0 |
The physician was asked, "How would you rate your overall satisfaction with the distant management of the participant during chemotherapy at home?" Choices included: "Very dissatisfied", "Somewhat dissatisfied", "Neither satisfied nor dissatisfied", "Somewhat satisfied", or "Very satisfied".
| investigators | Pemetrexed |
|---|---|
| Very Dissatisfied | 2 |
| Somewhat Dissatisfied | 1 |
| Neither Satisfied Nor Dissatisfied | 0 |
| Somewhat Satisfied | 8 |
| Very Satisfied | 20 |
The number of participants who had at least 1 unplanned use of health care resources \[accident and emergency department (dept.), specialists \[oncologist, pulmonologist, etcetera (etc.)\], general practitioner (GP) or family doctor, or diagnostic procedures\] during the study is reported.
| participants | Pemetrexed |
|---|---|
| Resource Utilization: Number of Participants With an Unplanned Use of Healthcare Resources | 29 |
The unplanned use of any 1 of the following 4 resources is reported, as well as the unplanned use of each resource: accident and emergency dept., specialists (oncologist, pulmonologist etc.), GP or family doctor, and diagnostic procedures. Results are reported as the number of participants with an unplanned resource use (visit) for a specified number of times.
| participants | Pemetrexed |
|---|---|
| 1 Unplanned Visit, Any Resource | 8 |
| 2 Unplanned Visits, Any Resource | 6 |
| 3 Unplanned Visits, Any Resource | 5 |
| 4 Unplanned Visits, Any Resource | 2 |
| 5 Unplanned Visits, Any Resource | 3 |
| 9 Unplanned Visits, Any Resource | 1 |
| 10 Unplanned Visits, Any Resource | 1 |
| 13 Unplanned Visits, Any Resource | 1 |
| 1 Unplanned Visit, Accident and Emergency Dept. | 7 |
| 2 Unplanned Visits, Accident and Emergency Dept. | 2 |
| 3 Unplanned Visits, Accident and Emergency Dept. | 2 |
| 1 Unplanned Visit, Specialist | 9 |
| 2 Unplanned Visits, Specialist | 3 |
| 5 Unplanned Visits, Specialist | 1 |
| 1 Unplanned Visit, GP or Family Doctor | 6 |
| 2 Unplanned Visits, GP or Family Doctor | 3 |
| 3 Unplanned Visits, GP or Family Doctor | 2 |
| 4 Unplanned Visits, GP or Family Doctor | 3 |
| 1 Unplanned Visit, Diagnostic procedures | 6 |
| 2 Unplanned Visits, Diagnostic procedures | 2 |
| 3 Unplanned Visits, Diagnostic procedures | 3 |
| 4 Unplanned Visits, Diagnostic procedures | 1 |
The number of participants who had at least 1 TEAE or serious TEAE (regardless of causality) is reported along with the number of participants who died (due to any cause) while on therapy or during treatment discontinuation follow-up (up to 6 months). TEAEs started on or after the date and time of first dose of study drug, or started prior to study drug but worsened after study drug started. Clinically significant events were defined as SAEs and other non-serious adverse events (AEs). A summary of SAEs and other non-serious AEs is located in the Reported Adverse Events module.
| participants | Pemetrexed |
|---|---|
| At least 1 TEAE | 51 |
| At least 1 Serious TEAE | 21 |
| Death, AE (fell, multiple injuries) | 1 |
| Death, Study Drug Toxicity (atypical pneumonia) | 1 |
| Death, Study Disease | 26 |
The duration of the health care visit in the home setting is reported. The visit started when the nurse arrived and included the entire treatment process. The visit ended when the nurse left the home setting. Due to the limited number of participants with evaluable data, results are reported for Cycles 2 through 4.
| hours | Pemetrexed |
|---|---|
| Cycle 2 (n=42) | 1.67 ± 0.493 |
| Cycle 3 (n=35) | 1.66 ± 0.683 |
| Cycle 4 (n=28) | 1.57 ± 0.311 |
The distance traveled is reported by region (Great Britain and Sweden) and includes the distance traveled by the participant from his/her home to the hospital (Cycle 1) and other cycles where the homecare nurse traveled from the hospital to the participant's home. Due to the limited number of participants with evaluable data, results are reported for Cycles 1 through 4.
| kilometers (km) | Pemetrexed |
|---|---|
| Cycle 1, Home to Hospital, Great Britain (n=25) | 19.7 ± 23.39 |
| Cycle 1, Home to Hospital, Sweden (n=7) | 30.7 ± 23.08 |
| Cycle 2, Hospital to Home, Great Britain (n=24) | 15.5 ± 13.12 |
| Cycle 2, Hospital to Home, Sweden (n=7) | 23.9 ± 23.93 |
| Cycle 3, Hospital to Home, Great Britain (n=11) | 23.8 ± 16.72 |
| Cycle 3, Hospital to Home, Sweden (n=4) | 17.5 ± 17.97 |
| Cycle 4, Hospital to Home, Great Britain (n=7) | 11.7 ± 8.75 |
| Cycle 4, Hospital to Home, Sweden (n=2) | 24.5 ± 27.58 |
The percentage of participants who were alive at Month 6 was calculated as a cumulative percentage by Kaplan-Meier survival analyses approach. For participants not known to have died as of the cut-off date, OS was censored as the last contact date (known alive).
| percentage of participants | Pemetrexed |
|---|---|
| Overall Survival (OS) at 6 Months | 73 (58.1 to 82.8) |
The time from the date of the first dose of study treatment (Cycle 1, Day 1) to the date of death from any cause, PD (clinical and objective), or discontinuation of pemetrexed due to toxicity. Response was defined using RECIST, v1.1 criteria. PD was defined as having at least a 20% increase in the sum of the longest diameter of target lesions and at a minimum 5 mm increase above nadir. TTF was censored at the date of the last visit for participants who did not discontinue pemetrexed, who were still alive, and who had not progressed.
| months | Pemetrexed |
|---|---|
| Time to Treatment Failure (TTF) | 3.0 (2.3 to 4.2) |
Collected over Baseline through study completion [up to Cycle 19 (21 days/cycle) or treatment discontinuation, plus up to 6 months post treatment discontinuation]. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pemetrexed | — | 23/52 (44.2%) | 51/52 (98.1%) |
| Event | Pemetrexed |
|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/52 |
| Lower respiratory tract infectionInfections and infestations | 3/52 |
| FallInjury, poisoning and procedural complications | 3/52 |
| AnaemiaBlood and lymphatic system disorders | 2/52 |
| Chest painGeneral disorders | 2/52 |
| PneumoniaInfections and infestations | 2/52 |
| Back painMusculoskeletal and connective tissue disorders | 2/52 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/52 |
| Atrial flutterCardiac disorders | 1/52 |
| Cardiac arrestCardiac disorders | 1/52 |
| Event | Pemetrexed |
|---|---|
| FatigueGeneral disorders | 20/52 |
| NauseaGastrointestinal disorders | 17/52 |
| AnaemiaBlood and lymphatic system disorders | 12/52 |
| CoughRespiratory, thoracic and mediastinal disorders | 12/52 |
| Decreased appetiteMetabolism and nutrition disorders | 9/52 |
| Back painMusculoskeletal and connective tissue disorders | 9/52 |
| LethargyNervous system disorders | 9/52 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 9/52 |
| ConstipationGastrointestinal disorders | 8/52 |
| HeadacheNervous system disorders | 8/52 |
Safety Population: Participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Pemetrexed |
|---|---|
| Median | 66.0 ± 12.05 |
| Sex: Female, Male(Participants) | Pemetrexed |
|---|---|
| Female | 26 |
| Male | 26 |
| Race/Ethnicity, Customized(participants) | Pemetrexed |
|---|---|
| White | 48 |
| Black or African American | 4 |
| Region of Enrollment(participants) | Pemetrexed |
|---|---|
| United Kingdom | 43 |
| Sweden | 9 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(participants) | Pemetrexed |
|---|---|
| 0: Fully Active | 14 |
| 1: Restricted | 38 |
| Most Recent Pathological Diagnosis(participants) | Pemetrexed |
|---|---|
| Adenocarcinoma, Lung | 48 |
| Adenocarcinoma, Mucinous, No Other Symptoms (NOS) | 1 |
| Adenocarcinoma, Moderately Differentiated, Lung | 1 |
| Carcinoma, Non-Small Cell, Lung NOS | 2 |
| Basis for Most Recent Pathological Diagnosis(participants) | Pemetrexed |
|---|---|
| Cytological | 10 |
| Histopathological | 42 |
| Stage of Disease(participants) | Pemetrexed |
|---|---|
| Stage IIIB | 3 |
| Stage IV | 48 |
| Stage IIIA | 1 |
2 further baseline measures are reported on the registry.
The record gives a start of Dec 2011, a primary completion of Sep 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pemetrexed
Carcinoma, Non-Small-Cell Lung →